

Christopher J Earley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9348818/publications.pdf>

Version: 2024-02-01

122
papers

11,456
citations

26630

56
h-index

28297

105
g-index

126
all docs

126
docs citations

126
times ranked

4171
citing authors

#	ARTICLE	IF	CITATIONS
1	Toward a better definition of the restless legs syndrome. <i>Movement Disorders</i> , 1995, 10, 634-642.	3.9	1,004
2	Restless Legs Syndrome. <i>Journal of Clinical Neurophysiology</i> , 2001, 18, 128-147.	1.7	474
3	Augmentation of the Restless Legs Syndrome With Carbidopa/Levodopa. <i>Sleep</i> , 1996, 19, 205-213.	1.1	424
4	Iron and The Restless Legs Syndrome. <i>Sleep</i> , 1998, 21, 381-387.	1.1	324
5	Restless Legs Syndrome. <i>New England Journal of Medicine</i> , 2003, 348, 2103-2109.	27.0	300
6	Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. <i>Brain</i> , 2009, 132, 2403-2412.	7.6	299
7	An Algorithm for the Management of Restless Legs Syndrome. <i>Mayo Clinic Proceedings</i> , 2004, 79, 916-922.	3.0	287
8	An Update on the Dopaminergic Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder. <i>Sleep</i> , 2004, 27, 560-583.	1.1	283
9	Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a World Association of Sleep Medicine "International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. <i>Sleep Medicine</i> , 2007, 8, 520-530.	1.6	264
10	Evaluating the quality of life of patients with restless legs syndrome. <i>Clinical Therapeutics</i> , 2004, 26, 925-935.	2.5	263
11	The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. <i>Sleep Medicine</i> , 2013, 14, 675-684.	1.6	260
12	Altered Brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom) Tj ETQqO 0,0.rgBT /Overlock 10	1.6	251
13	The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("œmimics"). <i>Sleep Medicine</i> , 2009, 10, 976-981.	1.6	246
14	The role of iron in restless legs syndrome. <i>Movement Disorders</i> , 2007, 22, S440-S448.	3.9	243
15	Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. <i>Sleep Medicine</i> , 2018, 41, 27-44.	1.6	228
16	MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. <i>Sleep Medicine</i> , 2006, 7, 458-461.	1.6	219
17	Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. <i>Sleep Medicine</i> , 2000, 1, 11-19.	1.6	211
18	Insight into the pathophysiology of restless legs syndrome. <i>Journal of Neuroscience Research</i> , 2000, 62, 623-628.	2.9	209

#	ARTICLE	IF	CITATIONS
19	Profile of altered brain iron acquisition in restless legs syndrome. <i>Brain</i> , 2011, 134, 959-968.	7.6	203
20	Cognitive deficits associated with restless legs syndrome (RLS). <i>Sleep Medicine</i> , 2006, 7, 25-30.	1.6	193
21	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 898-907.	10.2	191
22	The treatment of restless legs syndrome with intravenous iron dextran. <i>Sleep Medicine</i> , 2004, 5, 231-235.	1.6	190
23	The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. <i>American Journal of Hematology</i> , 2013, 88, 261-264.	4.1	189
24	Pergolide and Carbidopa/Levodopa Treatment of the Restless Legs Syndrome and Periodic Leg Movements in Sleep in a Consecutive Series of Patients. <i>Sleep</i> , 1996, 19, 801-810.	1.1	184
25	Restless legs syndrome: Understanding its consequences and the need for better treatment. <i>Sleep Medicine</i> , 2010, 11, 807-815.	1.6	165
26	Validation of the Johns Hopkins restless legs severity scale. <i>Sleep Medicine</i> , 2001, 2, 239-242.	1.6	162
27	A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. <i>Sleep Medicine</i> , 2011, 12, 440-444.	1.6	159
28	Thalamic glutamate/glutamine in restless legs syndrome. <i>Neurology</i> , 2013, 80, 2028-2034.	1.1	156
29	Willis-Ekbom Disease Foundation Revised Consensus Statement on the Management of Restless Legs Syndrome. <i>Mayo Clinic Proceedings</i> , 2013, 88, 977-986.	3.0	131
30	Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: A multi-centred, placebo-controlled preliminary clinical trial. <i>Sleep Medicine</i> , 2011, 12, 906-913.	1.6	126
31	The Dopamine Transporter is Decreased in the Striatum of Subjects with Restless Legs Syndrome. <i>Sleep</i> , 2011, 34, 341-347.	1.1	126
32	Epidemiology of Restless Legs Syndrome in Korean Adults. <i>Sleep</i> , 2008, 31, 219-223.	1.1	119
33	A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. <i>Sleep Medicine</i> , 2009, 10, 206-211.	1.6	114
34	Validation of the Restless Legs Syndrome Quality of Life Questionnaire. <i>Value in Health</i> , 2005, 8, 157-167.	0.3	105
35	Ferritin Levels in the Cerebrospinal Fluid and Restless Legs Syndrome: Effects of Different Clinical Phenotypes. <i>Sleep</i> , 2005, 28, 1069-1075.	1.1	104
36	Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. <i>Sleep Medicine</i> , 2005, 6, 301-305.	1.6	101

#	ARTICLE	IF	CITATIONS
37	Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. <i>Sleep Medicine</i> , 2008, 9, 283-289.	1.6	100
38	Increased Synaptic Dopamine in the Putamen in Restless Legs Syndrome. <i>Sleep</i> , 2013, 36, 51-57.	1.1	93
39	Restless legs syndrome augmentation associated with tramadol. <i>Sleep Medicine</i> , 2006, 7, 592-593.	1.6	92
40	Pregnancy accounts for most of the gender difference in prevalence of familial RLS. <i>Sleep Medicine</i> , 2010, 11, 310-313.	1.6	90
41	The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. <i>Sleep Medicine</i> , 2003, 4, 137-141.	1.6	86
42	Circadian changes in CSF dopaminergic measures in restless legs syndrome. <i>Sleep Medicine</i> , 2006, 7, 263-268.	1.6	85
43	Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. <i>Sleep Medicine</i> , 2009, 10, 123-128.	1.6	85
44	New Insights into the Neurobiology of Restless Legs Syndrome. <i>Neuroscientist</i> , 2019, 25, 113-125.	3.5	85
45	Augmentation as a treatment complication of restless legs syndrome: Concept and management. <i>Movement Disorders</i> , 2007, 22, S476-S484.	3.9	81
46	Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. <i>Journal of Neurochemistry</i> , 2008, 106, 205-215.	3.9	76
47	The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. <i>Sleep Medicine</i> , 2009, 10, 1155-1157.	1.6	75
48	Is ferroportin-hepcidin signaling altered in restless legs syndrome?. <i>Journal of the Neurological Sciences</i> , 2006, 247, 173-179.	0.6	73
49	Postmortem and imaging based analyses reveal CNS decreased myelination in restless legs syndrome. <i>Sleep Medicine</i> , 2011, 12, 614-619.	1.6	72
50	Ferritin subunits in CSF are decreased in restless legs syndrome. <i>Translational Research</i> , 2006, 147, 67-73.	2.3	70
51	Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla. <i>Sleep Medicine</i> , 2016, 22, 75-82.	1.6	70
52	CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. <i>Movement Disorders</i> , 2001, 16, 144-149.	3.9	69
53	Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome. <i>Journal of the Neurological Sciences</i> , 2004, 220, 59-66.	0.6	69
54	Mitochondrial Ferritin in the Substantia Nigra in Restless Legs Syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 1193-1199.	1.7	68

#	ARTICLE	IF	CITATIONS
55	The Management of Restless Legs Syndrome: An Updated Algorithm. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1921-1937.	3.0	67
56	Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. <i>Frontiers in Neuroscience</i> , 2017, 11, 722.	2.8	64
57	Functional connectivity alternation of the thalamus in restless legs syndrome patients during the asymptomatic period: a resting-state connectivity study using functional magnetic resonance imaging. <i>Sleep Medicine</i> , 2014, 15, 289-294.	1.6	63
58	Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willisâ€™Ekbom disease). <i>Sleep Medicine</i> , 2014, 15, 1473-1476.	1.6	55
59	Lower molecular weight intravenous iron dextran for restless legs syndrome. <i>Sleep Medicine</i> , 2013, 14, 274-277.	1.6	54
60	Low brain iron effects and reversibility on striatal dopamine dynamics. <i>Experimental Neurology</i> , 2014, 261, 462-468.	4.1	52
61	Targeting hypersensitive corticostriatal terminals in restless legs syndrome. <i>Annals of Neurology</i> , 2017, 82, 951-960.	5.3	52
62	The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome. <i>Mayo Clinic Proceedings</i> , 2018, 93, 59-67.	3.0	47
63	The effects of dietary iron deprivation on murine circadian sleep architecture. <i>Sleep Medicine</i> , 2006, 7, 634-640.	1.6	46
64	Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. <i>Sleep Medicine</i> , 2016, 25, 16-23.	1.6	46
65	Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. <i>Sleep Medicine</i> , 2017, 31, 71-77.	1.6	46
66	Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. <i>Neuropharmacology</i> , 2016, 111, 160-168.	4.1	45
67	Diurnal cycle influences peripheral and brain iron levels in mice. <i>Journal of Applied Physiology</i> , 2009, 106, 187-193.	2.5	38
68	Systems genetic analysis of the effects of iron deficiency in mouse brain. <i>Neurogenetics</i> , 2012, 13, 147-157.	1.4	36
69	Gray matter alteration in patients with restless legs syndrome: a voxel-based morphometry study. <i>Clinical Imaging</i> , 2015, 39, 20-25.	1.5	36
70	Segregation Analysis of Restless Legs Syndrome: Possible Evidence for a Major Gene in a Family Study Using Blinded Diagnoses. <i>Human Heredity</i> , 2006, 62, 157-164.	0.8	35
71	Altered Iron Metabolism in Lymphocytes from Subjects with Restless Legs Syndrome. <i>Sleep</i> , 2008, 31, 847-852.	1.1	35
72	In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. <i>Sleep Medicine</i> , 2017, 31, 86-92.	1.6	34

#	ARTICLE	IF	CITATIONS
73	Prevalence and clinical characteristics of patients with restless legs syndrome with painful symptoms. <i>Sleep Medicine</i> , 2015, 16, 775-778.	1.6	33
74	Proteomic analysis of the cerebrospinal fluid of patients with restless legs syndrome/Willis-Ekbom disease. <i>Fluids and Barriers of the CNS</i> , 2013, 10, 20.	5.0	32
75	Iron Deficiency Alters the Day-Night Variation in Monoamine Levels in Mice. <i>Chronobiology International</i> , 2009, 26, 447-463.	2.0	31
76	Diurnal variation of default mode network in patients with restless legs syndrome. <i>Sleep Medicine</i> , 2018, 41, 1-8.	1.6	29
77	Altered white matter integrity in primary restless legs syndrome patients: diffusion tensor imaging study. <i>Neurological Research</i> , 2014, 36, 769-774.	1.3	28
78	Up-regulation of striatal adenosine A2A receptors with iron deficiency in rats. <i>Experimental Neurology</i> , 2010, 224, 292-298.	4.1	27
79	Association of Restless Legs Syndrome Variants in Korean Patients with Restless Legs Syndrome. <i>Sleep</i> , 2013, 36, 1787-1791.	1.1	27
80	Default mode network disturbances in restless legs syndrome/Willis-Ekbom disease. <i>Sleep Medicine</i> , 2016, 23, 6-11.	1.6	27
81	Systems genetic analysis of peripheral iron parameters in the mouse. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R116-R124.	1.8	25
82	RLS and blood donation. <i>Sleep Medicine</i> , 2009, 10, 844-849.	1.6	24
83	Systems genetic analysis of multivariate response to iron deficiency in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2012, 302, R1282-R1296.	1.8	24
84	A direct interaction between two Restless Legs Syndrome predisposing genes: MEIS1 and SKOR1. <i>Scientific Reports</i> , 2018, 8, 12173.	3.3	23
85	Diminished iron concentrations increase adenosine A2A receptor levels in mouse striatum and cultured human neuroblastoma cells. <i>Experimental Neurology</i> , 2009, 215, 236-242.	4.1	22
86	We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments. <i>Sleep Medicine Reviews</i> , 2021, 58, 101461.	8.5	22
87	Restless legs syndrome and periodic leg movements in sleep. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2011, 99, 913-948.	1.8	21
88	MATPLM1, A MATLAB script for scoring of periodic limb movements: preliminary validation with visual scoring. <i>Sleep Medicine</i> , 2015, 16, 1541-1549.	1.6	18
89	Investigation into the correlation between sensation and leg movement in restless legs syndrome. <i>Movement Disorders</i> , 2005, 20, 1097-1103.	3.9	17
90	Dissociative Changes in the B _{max} and K _D of Dopamine D ₂ /D ₃ Receptors with Aging Observed in Functional Subdivisions of the Striatum: A Revisit with an Improved Data Analysis Method. <i>Journal of Nuclear Medicine</i> , 2012, 53, 805-812.	5.0	17

#	ARTICLE	IF	CITATIONS
91	Efficacy of ferric carboxymaltose (FCM) 500Âmg dose for the treatment of Restless Legs Syndrome. <i>Sleep Medicine</i> , 2018, 42, 7-12.	1.6	16
92	Brain-iron deficiency models of restless legs syndrome. <i>Experimental Neurology</i> , 2022, 356, 114158.	4.1	16
93	Moderate to severe but not mild RLS is associated with greater sleep-related sympathetic autonomic activation than healthy adults without RLS. <i>Sleep Medicine</i> , 2020, 68, 89-95.	1.6	15
94	Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome. <i>Sleep Medicine</i> , 2020, 71, 141-148.	1.6	15
95	Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome. <i>Sleep</i> , 2019, 42, .	1.1	13
96	Brain Iron Deficiency Changes the Stoichiometry of Adenosine Receptor Subtypes in Cortico-Striatal Terminals: Implications for Restless Legs Syndrome. <i>Molecules</i> , 2022, 27, 1489.	3.8	11
97	A comparison of MRI tissue relaxometry and ROI methods used to determine regional brain iron concentrations in restless legs syndrome. <i>Medical Devices: Evidence and Research</i> , 2015, 8, 341.	0.8	9
98	Co-registration of magnetic resonance spectroscopy and transcranial magnetic stimulation. <i>Journal of Neuroscience Methods</i> , 2015, 242, 52-57.	2.5	9
99	Resting-state connectivity and the effects of treatment in restless legs syndrome. <i>Sleep Medicine</i> , 2020, 67, 33-38.	1.6	9
100	Akathisia and Restless Legs Syndrome. <i>Sleep Medicine Clinics</i> , 2021, 16, 249-267.	2.6	9
101	Inter-movement interval as a primary stable measure of periodic limb movements of sleep. <i>Sleep Medicine</i> , 2016, 17, 138-143.	1.6	8
102	Latest Guidelines and Advances for Treatment of Restless Legs Syndrome. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e08.	2.2	8
103	Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. <i>Sleep Medicine</i> , 2021, 84, 179-186.	1.6	7
104	Evidence for communication of peripheral iron status to cerebrospinal fluid: clinical implications for therapeutic strategy. <i>Fluids and Barriers of the CNS</i> , 2020, 17, 28.	5.0	6
105	Defining morphology of periodic leg movements in sleep: an evidence-based definition of a minimum window of sustained activity. <i>Sleep and Breathing</i> , 2016, 20, 1293-1299.	1.7	5
106	Response to Clinical Corners case (<i>Sleep Medicine</i> 6/2: 83â€“4): Pregnancy associated with daytime sleepiness and nighttime restlessness. <i>Sleep Medicine</i> , 2005, 6, 475.	1.6	4
107	Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis. <i>Sleep Medicine</i> , 2017, 38, 44-49.	1.6	4
108	Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period. <i>Sleep Medicine</i> , 2018, 52, 80-87.	1.6	4

#	ARTICLE	IF	CITATIONS
109	Developing a behavioral model of Restless Legs Syndrome utilizing mice with natural variances in ventral midbrain iron. <i>Sleep Medicine</i> , 2020, 71, 135-140.	1.6	4
110	Pilot study: can machine learning analyses of movement discriminate between leg movements in sleep (LMS) with vs. without cortical arousals?. <i>Sleep and Breathing</i> , 2021, 25, 373-379.	1.7	4
111	Developing a biomarker for restless leg syndrome using genome wide DNA methylation data. <i>Sleep Medicine</i> , 2021, 78, 120-127.	1.6	4
112	Intervening Leg Movements Disrupt PLMS Sequences. <i>Sleep</i> , 2017, 40, .	1.1	3
113	Neuroimaging in Restless Legs Syndrome. , 2009, , 78-82.		3
114	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients. <i>Frontiers in Neurology</i> , 2021, 12, 786408.	2.4	2
115	RestEaze: An Emerging Technology to Characterize Leg Movements During Sleep. <i>Journal of Medical Devices, Transactions of the ASME</i> , 2022, 16, .	0.7	2
116	Iron Dysregulation in Restless Legs Syndrome. , 2009, , 61-68.		1
117	Another dopamine agonist for treatment of restless legs syndrome. <i>Lancet Neurology</i> , The, 2011, 10, 675-677.	10.2	1
118	Response to the letter "Characterization of the painful restless legs syndrome". <i>Sleep Medicine</i> , 2015, 16, 1448.	1.6	1
119	Insight into the pathophysiology of restless legs syndrome. <i>Journal of Neuroscience Research</i> , 2000, 62, 623-628.	2.9	1
120	Role of Striatal A2A Receptor Subpopulations in Neurological Disorders. , 2013, , 179-197.		1
121	Response to "Characterization of the painful restless legs syndrome". <i>Sleep Medicine</i> , 2015, 16, 898.	1.6	0
122	Altered expression of iron management proteins in the brain microvasculature of Restless Legs Syndrome. <i>FASEB Journal</i> , 2008, 22, 1191.5.	0.5	0